Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STR-P004 in R/R CD19+ B-ALL
NCT07245251Phase 1Not yet recruiting
- Sponsor
- Starna Therapeutics
- Start
- Dec 2025
- Primary completion
- Nov 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of STR-P004 in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Starna Therapeutics. Primary endpoint: Safety and tolerability endpoints at 12 months. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
STR-P004
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT07245251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07245251.